Regeneron Pharmaceuticals Inc
- Industry
- Pharmaceuticals
- Exchange
- US
- Country
- USA
- IPO date
- Apr 2, 1991
- Employees
- 15,343
- Website
- www.regeneron.com
Composite valuation range · conservative $450–$550 / fair $550–$700 / optimistic $700–$850. At $667.17, Within the fair intrinsic-value range.
At publication $642.59 (May 22, 2026)
Data from EODHD, shown in the reporting currency; for reference only, not investment advice.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.
History
Regeneron Pharmaceuticals, Inc. was incorporated in 1988 and is based in Tarrytown, New York, completing its IPO on April 2, 1991. The company has built a portfolio of license and collaboration agreements, including with Sanofi (Dupixent, Kevzara) and Bayer (EYLEA 8 mg and EYLEA), alongside agreements with Alnylam, Intellia, Hansoh, Tessera, Telix, and CytomX. EYLEA's U.S. regulatory exclusivity ended in May 2024, and the company began paying its first cash dividend in 2025, with its board adding a $3 billion buyback authorization in April 2026.
Industry position
Regeneron is a fully integrated biotechnology company in the Healthcare sector that discovers, develops, manufactures, and commercializes medicines, managing its business as a single operating segment. In 2025 total revenue was $14.34 billion, split between $6.31 billion of product sales and $7.33 billion of collaboration revenue. Dupixent reached $17.8 billion in global sales in 2025. Across markets it competes with Roche/Genentech's Vabysmo and Amgen's Pavblu in ophthalmology, and with Lilly's Ebglyss, AbbVie's Rinvoq, and Pfizer's Cibinqo in immunology and inflammation. The company has about 15,343 employees.